retatrutide weight loss injection Results:Trial Data and FDA Status Seeking Differentiation Through a Triple

If you experience a suspected side effect from any medicine or supplement, you can report it to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk

Providing a treatment option that is proven to lower this cardiovascular risk is a major advance for public health. The FDAs decision is largely based on data from the SELECT trial, which included more than 17,000 overweight or obese patients with a baseline age of 45 years old

and 85-126 (see Figure 3a inset)

According to a 2025 review published in Nature Bone Research , rapid weight loss is associated with approximately 1% to 3% BMD loss for every 10% of body weight lost